Panitumumab. en las nuevas guías de CCRm - page 13

PRIME study RAS analysis
PFS, OS (by RAS and BRAF status, primary analysis)
• Douillard JY, et al. N Engl J Med 2013; 369:1023-34.• WT RAS , WT KRAS & NRAS exons 2/3/4
• (includes 7 patients harbouring KRAS/NRAS codon 59 mutations); WT RAS & BRAF, WT KRAS &
NRAS exons 2/3/4 & BRAF exon 15;
• NE, not evaluated
Variable
Panitumumab +
FOLFOX4 FOLFOX4
Hazard
ratio P-value
WT RAS/WT BRAF, n 228 218
Median PFS, months
(95% CI)
10.8
(9.4–12.4)
9.2
(7.4–9.6)
0.68
(0.54–0.87)
0.002
Median OS, months
(95% CI)
28.3
(23.7–NE)
20.9
(18.4–23.8)
0.74
(0.57–0.96)
0.02
WT RAS/MT BRAF, n 24 29
Median PFS, months
(95% CI)
6.1
(3.7–10.7)
5.4
(3.3–6.2)
0.58
(0.29–1.15)
0.12
Median OS, months
(95% CI)
10.5
(6.4–18.9)
9.2
(8.0–15.7)
0.90
(0.46–1.76)
0.76